Adam D. Teitcher

Adam has a proven ability to manage, motivate, and lead teams in high-pressure and complex matters. Most recently, Adam served as trial counsel for one of the world’s largest manufacturers of generic pharmaceutical products and obtained a complete defense victory in the national opioid litigation in Orange County, California Superior Court. The trial, which was the culmination of seven years of litigation, lasted more than four months and secured the first trial defense win in the national opioid litigation. Adam built the case leading up to trial and was critical in developing and implementing case and trial strategy. Adam has since served as trial counsel in other opioid litigation trials across the country, including in Rhode Island and San Francisco. The Rhode Island trial settled just as opening statements were to begin, and the San Francisco trial settled just before closing arguments, after more than two months of trial.

Adam maintains an active pro bono practice, covering election and voting rights, immigration, and civil rights.

• Representing international pharmaceutical company in action challenging marketing and branding of opioid medications.
• Representing national marketplace of home services provider against claims of false advertising and unfair competition.
• Represented hedge fund against insider trading claims in multi-billion dollar securities fraud matter.
• Obtained favorable results in New York state trial and appellate courts defending business developer’s $400+ million development against opposition group of local and competing businesses.
• Pro bono counsel for civic organization in case brought against federal election officials in two states, alleging violations of the Constitution, the National Voter Registration Act, and the Administrative Procedure Act.
• Conducted internal investigations on behalf of public companies in response to allegations of possible accounting fraud and in response to requests from the Department
• Advised companies of FDA and FAA regulatory compliance.